Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018.

Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE.

J Pharmacol Exp Ther. 2019 May;369(2):259-269. doi: 10.1124/jpet.118.252965. Epub 2019 Mar 4.

PMID:
30833484
2.

Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22).

Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R.

Xenobiotica. 2019 Feb 9:1-8. doi: 10.1080/00498254.2019.1580403. [Epub ahead of print]

PMID:
30739533
3.

Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC.

Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL.

Front Pharmacol. 2018 Sep 26;9:1084. doi: 10.3389/fphar.2018.01084. eCollection 2018.

4.

The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects.

Franks LN, Ford BM, Fujiwara T, Zhao H, Prather PL.

Toxicol Appl Pharmacol. 2018 Aug 15;353:31-42. doi: 10.1016/j.taap.2018.06.009. Epub 2018 Jun 12.

PMID:
29906493
5.

Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants.

Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A.

Biochem Biophys Res Commun. 2018 Apr 6;498(3):597-602. doi: 10.1016/j.bbrc.2018.03.028. Epub 2018 Mar 10.

6.

Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome?

Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M.

Neurosci Lett. 2018 Apr 23;673:24-27. doi: 10.1016/j.neulet.2018.02.054. Epub 2018 Feb 25.

7.

Preface to DMR special edition 'Cannabinoid receptors and ligands: therapeutic drug development and abuse potential'.

Prather PL.

Drug Metab Rev. 2018 Feb;50(1):1-2. doi: 10.1080/03602532.2018.1431657. Epub 2018 Jan 30. No abstract available.

8.

Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy.

Yadlapalli JSK, Dogra N, Walbaum AW, Prather PL, Crooks PA, Dobretsov M.

Life Sci. 2018 Jan 1;192:151-159. doi: 10.1016/j.lfs.2017.11.042. Epub 2017 Nov 28.

PMID:
29191644
9.

The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.

Crowe MS, Wilson CD, Leishman E, Prather PL, Bradshaw HB, Banks ML, Kinsey SG.

Br J Pharmacol. 2017 Dec;174(23):4523-4539. doi: 10.1111/bph.14055. Epub 2017 Nov 20.

10.

Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.

Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL.

Pharmacol Res. 2017 Nov;125(Pt B):161-177. doi: 10.1016/j.phrs.2017.08.008. Epub 2017 Aug 23.

11.

Evaluation of Analgesia, Tolerance, and the Mechanism of Action of Morphine-6-O-Sulfate Across Multiple Pain Modalities in Sprague-Dawley Rats.

Yadlapalli JSK, Dogra N, Walbaum AW, Wessinger WD, Prather PL, Crooks PA, Dobretsov M.

Anesth Analg. 2017 Sep;125(3):1021-1031. doi: 10.1213/ANE.0000000000002006.

12.

Synthetic Pot: Not Your Grandfather's Marijuana.

Ford BM, Tai S, Fantegrossi WE, Prather PL.

Trends Pharmacol Sci. 2017 Mar;38(3):257-276. doi: 10.1016/j.tips.2016.12.003. Epub 2017 Feb 2. Review.

13.

Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity.

Franks LN, Ford BM, Prather PL.

Front Pharmacol. 2016 Dec 22;7:503. doi: 10.3389/fphar.2016.00503. eCollection 2016.

14.

Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.

Ford BM, Franks LN, Radominska-Pandya A, Prather PL.

PLoS One. 2016 Dec 9;11(12):e0167240. doi: 10.1371/journal.pone.0167240. eCollection 2016.

15.

Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.

Yadlapalli JSK, Ford BM, Ketkar A, Wan A, Penthala NR, Eoff RL, Prather PL, Dobretsov M, Crooks PA.

Pharmacol Res. 2016 Nov;113(Pt A):335-347. doi: 10.1016/j.phrs.2016.09.012. Epub 2016 Sep 13.

16.

Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity.

Jalin AM, Rajasekaran M, Prather PL, Kwon JS, Gajulapati V, Choi Y, Kim C, Pahk K, Ju C, Kim WK.

PLoS One. 2015 Oct 30;10(10):e0141600. doi: 10.1371/journal.pone.0141600. eCollection 2015.

17.
18.

Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.

Franks LN, Ford BM, Madadi NR, Penthala NR, Crooks PA, Prather PL.

Eur J Pharmacol. 2014 Aug 15;737:140-8. doi: 10.1016/j.ejphar.2014.05.007. Epub 2014 May 20.

19.

In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection.

Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE.

Pharmacol Biochem Behav. 2014 Sep;124:40-7. doi: 10.1016/j.pbb.2014.05.010. Epub 2014 May 21.

20.

Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner.

Wang J, Zheng J, Kulkarni A, Wang W, Garg S, Prather PL, Hauer-Jensen M.

Dig Dis Sci. 2014 Nov;59(11):2693-703. doi: 10.1007/s10620-014-3212-5. Epub 2014 May 22.

21.

Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds.

Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH.

Forensic Sci Int. 2013 Dec 10;233(1-3):416-22. doi: 10.1016/j.forsciint.2013.10.002. Epub 2013 Oct 14.

PMID:
24314548
22.

CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.

Prather PL, FrancisDevaraj F, Dates CR, Greer AK, Bratton SM, Ford BM, Franks LN, Radominska-Pandya A.

Biochem Biophys Res Commun. 2013 Nov 15;441(2):339-43. doi: 10.1016/j.bbrc.2013.10.057. Epub 2013 Oct 19.

23.

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL.

Life Sci. 2014 Feb 27;97(1):45-54. doi: 10.1016/j.lfs.2013.09.017. Epub 2013 Sep 29. Review.

24.

The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Brents LK, Prather PL.

Drug Metab Rev. 2014 Feb;46(1):72-85. doi: 10.3109/03602532.2013.839700. Epub 2013 Sep 24. Review.

25.

Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.

Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE.

J Pharmacol Exp Ther. 2013 Sep;346(3):350-61. doi: 10.1124/jpet.113.206003. Epub 2013 Jun 25.

26.

Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.

Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE.

J Med Chem. 2013 Jun 13;56(11):4537-50. doi: 10.1021/jm400268b. Epub 2013 May 22.

27.

Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL.

Toxicol Appl Pharmacol. 2013 Jun 1;269(2):100-8. doi: 10.1016/j.taap.2013.03.012. Epub 2013 Mar 26.

28.

Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors.

Madadi NR, Penthala NR, Brents LK, Ford BM, Prather PL, Crooks PA.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):2019-21. doi: 10.1016/j.bmcl.2013.02.025. Epub 2013 Feb 14.

29.

Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury.

Choi IY, Ju C, Anthony Jalin AM, Lee DI, Prather PL, Kim WK.

Am J Pathol. 2013 Mar;182(3):928-39. doi: 10.1016/j.ajpath.2012.11.024. Epub 2013 Feb 13.

PMID:
23414569
30.

Differential anti-ischemic efficacy and therapeutic time window of trans- and cis-hinokiresinols: stereo-specific antioxidant and anti-inflammatory activities.

Ju C, Hwang S, Cho GS, Kondaji G, Song S, Prather PL, Choi Y, Kim WK.

Neuropharmacology. 2013 Apr;67:465-75. doi: 10.1016/j.neuropharm.2012.12.006. Epub 2013 Jan 1.

PMID:
23287539
31.

Effects of the β-agonist, isoprenaline, on the down-regulation, functional responsiveness and trafficking of β2-adrenergic receptors with N-terminal polymorphisms.

Koryakina Y, Jones SM, Cornett LE, Seely K, Brents L, Prather PL, Kofman A, Kurten RC.

Cell Biol Int. 2012;36(12):1171-83. doi: 10.1042/CBI20120134.

32.

Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH.

Drug Metab Dispos. 2012 Nov;40(11):2174-84. doi: 10.1124/dmd.112.047530. Epub 2012 Aug 17.

33.

AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL.

Neuropharmacology. 2012 Oct;63(5):905-15. doi: 10.1016/j.neuropharm.2012.06.046. Epub 2012 Jul 4.

34.

Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs.

Safe SH, Prather PL, Brents LK, Chadalapaka G, Jutooru I.

Anticancer Agents Med Chem. 2012 Dec;12(10):1211-20. Review.

35.

Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer.

Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S.

Mol Cancer Ther. 2012 Jul;11(7):1421-31. doi: 10.1158/1535-7163.MCT-12-0026. Epub 2012 May 2.

36.

A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.

Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL.

Chem Res Toxicol. 2012 Apr 16;25(4):825-7. doi: 10.1021/tx3000472. Epub 2012 Mar 15.

37.

Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL.

Biochem Pharmacol. 2012 Apr 1;83(7):952-61. doi: 10.1016/j.bcp.2012.01.004. Epub 2012 Jan 18.

38.

Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors.

Brents LK, Medina-Bolivar F, Seely KA, Nair V, Bratton SM, Nopo-Olazabal L, Patel RY, Liu H, Doerksen RJ, Prather PL, Radominska-Pandya A.

Xenobiotica. 2012 Feb;42(2):139-56. doi: 10.3109/00498254.2011.609570. Epub 2011 Oct 4.

39.

Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.

Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL.

PLoS One. 2011;6(7):e21917. doi: 10.1371/journal.pone.0021917. Epub 2011 Jul 6.

40.

Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine.

Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH.

Anal Chem. 2011 Jun 1;83(11):4228-36. doi: 10.1021/ac2005636. Epub 2011 May 6.

41.

Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?

Seely KA, Prather PL, James LP, Moran JH.

Mol Interv. 2011 Feb;11(1):36-51. doi: 10.1124/mi.11.1.6. Review.

42.

Notice of retraction.

Prather PL, Seely KA, Levi MS.

J Pharmacol Exp Ther. 2009 Dec;331(3):1147. No abstract available.

PMID:
19940110
43.
44.

Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids.

Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radomińska-Pandya A, Moran JH.

Drug Metab Dispos. 2009 Jul;37(7):1496-504. doi: 10.1124/dmd.109.026898. Epub 2009 Apr 1.

45.

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.

Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL.

J Neurochem. 2007 Apr;101(1):87-98. Epub 2007 Jan 4.

46.

Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors.

Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL.

J Pharmacol Exp Ther. 2005 Nov;315(2):828-38. Epub 2005 Aug 4.

PMID:
16081674
47.

The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.

Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL.

J Pharmacol Exp Ther. 2005 Aug;314(2):868-75. Epub 2005 May 18.

PMID:
15901805
48.

Mechanism of bradykinin-induced Ca2+ mobilization in murine proximal tubule epithelial cells.

Tiwari MM, Prather PL, Mayeux PR.

J Pharmacol Exp Ther. 2005 May;313(2):798-805. Epub 2005 Jan 21.

PMID:
15665141
49.
50.

Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.

Liu JG, Prather PL.

J Pharmacol Exp Ther. 2002 Sep;302(3):1070-9.

PMID:
12183665

Supplemental Content

Loading ...
Support Center